Service Improvements and Workload Increases: Royal College of Radiologists (RCR) Re-Audit of Curative Intent Radiotherapy for Non-Small Cell Lung Cancer (NSCLC)

Autor: Bedair, A., Williams, A., James, A., Visioli, A., Sykes, A., Mitra, A., Haridass, A., Gore, A., Mirza, A., Stilwell, C., Sherriff, D., Wingate, E., Bainbridge, H., Ariyaratne, H., Phillips, I., Sham, J., Clarke, J., Pang, J., Brady, J., Tay, J., Frew, J., Adams, J., Thippu Jayaprakash, K., Tarver, K., Harihar, L., Churn, M., Griffin, M., Osborne, M., Button, M., Panades Piza, M., Bayne, M., Kagzi, M., Sivaramalingam, M., Dorey, N., Panakis, N., Goyal, N., Hatcher, O., Fenton, P., Wells, P., Lewis, P., Jain, P., Das, P., Roy, R., Goldfinch, R., Casasola, R., Sandoughdaran, S., Treece, S., Thamakulasingam, S., Lalondrelle, S., Walter, S., Durga, T., Talbot, T., Barthakur, U., Sangha, V., Gibson, V., Owadally, W., Dubash, S., McAleese, J., Drinkwater, K.

Publikováno v: In Clinical Oncology June 2024 36(6):e128-e136

Devitrification behavior and preferred crystallization mechanism of glasses based on fluorrichterite (Na2CaMg5Si8O22F2) composition

Autor: Casasola, R., Pérez, J.M., Romero, M.

Publikováno v: In Thermochimica Acta 10 November 2015 619:32-40

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Nucleation and crystallisation kinetics of a Na-fluorrichterite based glass by differential scanning calorimetry (DSC)

Autor: Pérez, J.M., Casasola, R., Rincón, J.Ma., Romero, M.

Publikováno v: In Journal of Non-Crystalline Solids 1 October 2012 358(20):2741-2748

Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial

Autor: Bottomley, A., Coens, C., Mierzynska, J., Blank, C. U., Mandalà, M., Long, G. V., Atkinson, V. G., Dalle, S., Haydon, A. M., Meshcheryakov, A., Khattak, A., Carlino, M. S., Sandhu, S., Puig, S., Ascierto, P. A., Larkin, J., Lorigan, P. C., Rutkowski, P., Schadendorf, D., Koornstra, R., Hernandez-Aya, L., Di Giacomo, A. M., van den Eertwegh, A. J. M., Grob, J. -J., Gutzmer, R., Jamal, R., van Akkooi, A. C. J., Krepler, C., Ibrahim, N., Marreaud, S., Kicinski, M., Suciu, S., Robert, C., Eggermont, A. M. M., EORTC Melanoma Group, Lesimple, T., Maio, M., Linette, G., Mortier, L., Svane, I. M., Schachter, J., Brown, M., Hersey, P., Barrow, C., Kudchadkar, R., Dutriaux, C., Song, X., Quaglino, P., Queirolo, P., Meier, F., Stroyakovskiy, D., Guillot, B., Romero, P. L. O., Bastholt, L., Garbe, C., Grange, F., Mohr, P., Algazi, A., Bechter, O., Hernberg, M., Loquai, C., Meiss, F., Chiarion Sileni, V., Bar-Sela, G., Fitzharris, B., Saiag, P., Arnault, J. -P., Simon, J. -C., Stephens, R., Baurain, J. -F., Lebbe, C., Combemale, P., Dummer, R., Hauschild, A., Parente, P., Yamazaki, N., Milhem, M., Leccia, M. -T., Geoffrois, L., Kretschmer, L., Dunwoodie, E., Walker, J., Lotem, M., Hendler, D., Mackiewicz, A., Sekulovic, L., Dzienis, M., Hospers, G. A. P., Siano, M., Hassel, J., Corrie, P., Passos, M. -J., Levin, M., Hoeller, C., Machet, L., Hallmeyer, S., Waterston, A., Descamps, V., Kiecker, F., Aarts, M., Schmidt, H., Raimundo, A., Nyakas, M., Lacour, J. -P., Berking, C., Ferrucci, P. F., Jameson, M., Kim, K., Yokota, K., Kerger, J., Aubin, F., Groenewegen, G., Kapiteijn, H., Boehncke, W. -H., Utikal, J., Casasola, R., Marshall, E., Ferraresi, V., Richtig, E., Matkovic, S., Inozume, T., Crook, T., Mcneil, C., Kiyohara, Y., Avril, M. -F., Hein, R., Terheyden, P., Nathan, P., Aoi, J., Skytta, T., Jouary, T., Takenouchi, T., Straume, O., Martins, C., Mukhametshina, G.

Publikováno v: Lancet. Oncology, Vol. 22, No 5 (2021) pp. 655-664
EORTC Melanoma Group 2021, ' Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial ', The Lancet Oncology, vol. 22, no. 5, pp. 655-664 . https://doi.org/10.1016/S1470-2045(21)00081-4
Lancet Oncology, 22, 5, pp. 655-664
The Lancet Oncology, 22(5), 655-664. Lancet Publishing Group
Lancet Oncology, 22, 655-664
Lancet Oncology
Lancet Oncology, 2021, 22 (5), pp.655-664. ⟨10.1016/S1470-2045(21)00081-4⟩
The Lancet Oncology, 22(5), 655-664. ELSEVIER SCIENCE INC

Background: The European Organisation for Research and Treatment of Cancer (EORTC) 1325-MG/KEYNOTE-054 trial in patients with resected, high-risk stage III melanoma demonstrated improved recurrence-free survival with adjuvant pembrolizumab compared w

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::80dc0ff7069bff303dade337b8effb2d
https://archive-ouverte.unige.ch/unige:159804